Dr. John Sheldon brought his experience with brachytherapy to bear with a targeted treatment for Barbie after her cervical cancer returned in 2015.
Radiation Oncologist Dr. John Sylvester, MD shared a few minutes with us at ABS 2018 discussing recent advancements in prostate brachytherapy and their implications for prostate cancer patients.
Dr. Sylvester discusses how the development of new technology can bring new treatment modalities that are frequently pressed upon patients in spite of brachytherapy’s efficacy and rapid side effect resolution.
Biological effectiveness dose and convenience: Why Cesium-131 is the LDR brachytherapy isotope of choice for Dr. Bradley Prestidge.
Dr. Bradley Prestidge, MD, MS, serves as Regional Medical Director of Radiation Oncology for Bon Secours Medical Group in Norfolk, Va. During the American Brachytherapy Society 2018 Annual Meeting, Dr. Prestidge shared with us his opinion on brachytherapy’s top...
New long-term data show brachytherapy boost improves freedom from biochemical failure outcomes for T3 high-risk prostate cancer by more than eight percent
In a new study, radiation oncologists find that DR-BT is not only feasible, but also highly effective in men with cT3a and cT3b high-risk prostate cancer.
Dr. John Sylvester Explores the Many Advantages of the Prostate Brachytherapy Procedure Over Surgery at ABS 2018
According to Dr. Sylvester, brachytherapy provides many advantages over surgery for prostate cancer treatment. This underscores the importance of prostate cancer patients becoming aware of brachytherapy as a treatment option.
Three recent peer-reviewed publications reinforce the value of brachytherapy as a treatment for prostate cancer
The past 12 to 18 months have seen remarkable new scientific evidence come to light regarding the attributes and benefits of brachytherapy, including Cesium-131, for prostate cancer treatment.
As the importance of patient involvement in determining their optimal post-treatment quality of life, these organizations educate and support the men and families affected by prostate cancer.
Dr. Brian J. Moran, Medical Director for the Chicago Prostate Cancer Center, stresses the importance of customizing each and every patient’s cancer treatment. “This disease is a spectrum disease,” says Moran.
“Today, over 85% of our [low-dose rate brachytherapy] patients are referred from former, satisfied patients,” says Moran. Because of this, Dr. Moran recognizes the value of brachytherapy in the community and the awareness in action. Former patients have even a monthly support group meeting that Dr. Moran and his Director of Research and Education attend.
Prostate cancer is one of the deadliest and most common cancers among men today. An article written by Melissa Matthews was recently published by Newsweek revealing that late detection plays a key role in why prostate cancer is so fatal.
Dr. Brian Moran, Medical Director for the Chicago Prostate Center, discusses the value of low-dose rate brachytherapy and its disruptive innovation in the cancer treatment field at ABS 2018.